A+ | A | A- | Skip to main content |

800 years stamp

Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Friday, 10 July 2026 12:00 AM EOD	Asian-Paints2677.80	Hind-Unilever2149.30	ITC281.90	Trent2902.75	Larsen-and-Toubro3946.55	M-and-M3129.15	Reliance-Industries1308.85	Tata-Steel191.15	Titan-Company4586.10	SBI1036.15	Bharat-Electron414.90	Kotak-Mah-Bank377.80	Infosys1068.05	Bajaj-Finance1020.45	Sun-PharmaInds1935.25	HDFC-Bank824.25	TCS2069.05	ICICI-Bank1401.45	Power-Grid-Corpn283.20	Maruti-Suzuki13859.25	Axis-Bank1323.75	HCL-Technologies1162.65	NTPC344.50	Bharti-Airtel1921.10	Tech-Mahindra1455.45	Adani-Ports1828.00	UltraTech-Cem11713.55	Bajaj-Finserv1915.55	Interglobe-Aviat5311.05	Eternal289.65
15 mins delay SENSEX 77,569.39 [827.57]	5.30 0.20%	5.20 0.24%	-0.05 -0.02%	-1.05 -0.04%	59.25 1.52%	43.90 1.42%	29.15 2.28%	3.35 1.78%	30.65 0.67%	14.50 1.42%	8.85 2.18%	0.75 0.20%	18.00 1.71%	17.15 1.71%	-3.60 -0.19%	6.55 0.80%	21.30 1.04%	19.85 1.44%	2.05 0.73%	130.85 0.95%	24.75 1.91%	13.05 1.14%	1.00 0.29%	-9.40 -0.49%	31.20 2.19%	28.70 1.60%	197.65 1.72%	21.30 1.12%	82.45 1.58%	-2.60 -0.89%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Emcure Pharma divests mRNA business for Rs 139.5 crore to Immunoscript Life Science

11-Jul-26 12:52Hrs IST

For FY2025-26, the revenue and the networth of the mRNA business of Gennova Biopharmaceuticals were Rs 64.71 crore (0.71% of consolidated revenue of Emcure Pharma) and Rs 132.63 crore (2.68% of consolidated net worth of Emcure Pharma), respectively.

The mRNA business business has been divested for a total cash consideration of Rs 139.5 crore. Emcure Pharma expects the transaction to be completed by 17 July 2026.

The company stated that the transfer of mRNA business is part of Gennova's strategic initiative to reorganize its business operations and focus on core areas, which are research and development, manufacturing and marketing of biotechnology-based products including biosimilars and adjacent therapeutic platforms.

Pune-based Emcure Pharmaceuticals develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally, including Europe and Canada.

On a consolidated basis, Emcure Pharmaceuticals' net profit rose 28.81% to Rs 243.40 crore while net sales rose 16.70% to Rs 2469.70 crore in Q4 March 2026 over Q4 March 2025.

The scrip rose 0.15% to end at Rs 1810.45 on the BSE on Friday.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise